Page last updated: 2024-12-08

noralfentanil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

noralfentanil: metabolite of sufentanil & alfentanil; structure given in first source; RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID162172
CHEBI ID174649
SCHEMBL ID3168327
MeSH IDM0136688

Synonyms (23)

Synonym
61086-18-8
CHEBI:174649
n-[4-(methoxymethyl)piperidin-4-yl]-n-phenylpropanamide
noralfentanil
n-(4-(methoxymethyl)piperidin-4-yl)-n-phenylpropionamide
unii-io6g3l550q
io6g3l550q ,
einecs 262-598-1
norsufentanil
n-(4-(methoxymethyl)piperidin-4-yl)-n-phenylpropanamide
sufentanil impurity a [ep impurity]
r30451
sufentanil citrate impurity a [ep impurity]
alfentanil hydrochloride hydrate impurity c [ep impurity]
r-30451
propanamide, n-(4-(methoxymethyl)-4-piperidinyl)-n-phenyl-
4-(n-(1-oxopropyl)-n-phenylamino)-4-(methoxymethyl)piperidine
n-[4-(methoxymethyl)piperidin-4-yl]-n-phenylpropionamide
ULOZGJWEIWAWML-UHFFFAOYSA-N
n-[4-(methoxymethyl)-4-piperidinyl]-n-phenylpropanamide
SCHEMBL3168327
DTXSID90209964
Q27280822
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
anilideAny aromatic amide obtained by acylation of aniline.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's5 (62.50)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.39 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]